This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by D'Andrea, M. R. Articles by Johnson, D. L. Search for Related Content PubMed PubMed Citation Articles by D'Andrea, M. R. Articles by Johnson, D. L.

Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Spring House, Pennsylvania

Requests for reprints: Michael R. D'Andrea, Drug Discovery, D404, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., P.O. Box 776, Welsh and McKean Roads, Spring House, PA 19477-0776. Phone: 215-628-5619; Fax: 215-540-4887. E-mail: mdandrea{at}prdus.jnj.com

With the advent of agents directed against specific molecular targets in drug discovery, it has become imperative to show a compound's cellular impact on the intended biomolecule in vivo. The objective of the present study was to determine if we could develop an assay to validate the in vivo effects of a compound. Hence, we investigated the in vivo pharmacodynamic activity of JNJ-10198409, a relatively selective inhibitor of platelet-derived growth factor receptor tyrosine kinase (PDGF-RTK), in tumor tissues after administering the compound orally in a nude mouse xenograft model of human LoVo colon cancer. We developed a novel assay to quantify the in vivo anti-PDGF-RTK activity of the inhibitor in tumor tissue by determining the phosphorylation status of phospholipase C1 (PLC1), a key downstream cellular molecule in the PDGF-RTK signaling cascade. We used two antibodies, one specific for the total (phosphorylated and unphosphorylated forms) PLC1 (pan-PLC1) and the other, specific for phosphorylated form of PLC1 (ph-PLC1) to immunohistochemically detect their expression in tumor tissues. Computer-assisted image analysis was then used to directly compare the ratio of ph-PLC1 to pan-PLC1 immunolabeling intensities in serial sections (5 µm) of tumors obtained from vehicle- and JNJ-10198409-treated tumor-bearing mice. Our data showed statistically significant, dose-dependent differences in the ph-PLC/pan-PLC ratio among the four treatment groups (vehicle, 25, 50, and 100 mg/kg b.i.d.). These results confirmed this compound's ability to suppress PDGF-RTK downstream signaling in tumor tissues in vivo. In addition to this specific application of this in vivo validation approach to those targets that use PLC as a downstream signaling partner, these methods may also benefit other drug discovery targets.

¹ Manuscript in preparation.

Received 1/ 5/05; revised 6/ 8/05; accepted 6/14/05.

This article has been cited by other articles:

				Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo Jr., et al. N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES Drug Metab. Dispos., May 1, 2006; 34(5): 748 - 755. [Abstract] [Full Text] [PDF]